Nat Rev Mol Cell Biol. 2025 Jan 24. IF: 81.3A guide to the biogenesis and functions of endogenous small non-coding RNAs in animals.www.nature.com/articles/s41580-024-00818-9 Nat Med. 2025 Jan 24. IF: 58.7Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial.www.nature.com/articles/s41591-024-03486-6 Cell. 2025 Jan 23. IF: 45.5High-resolution spatially resolved proteomics of complex tissues based on microfluidics and transfer learning.www.cell.com/cell/fulltext/S0092-8674(24)01436-3 J Clin Oncol. 2025 Jan 24. IF: 42.1Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.www.ascopubs.org/doi/10.1200/JCO-24-01673 J Hematol Oncol. 2025 Jan 23;18(1):9. IF: 29.5WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.www.biomedcentral.com/articles/10.1186/10.1186/s13045-025-01661-x Annu Rev Pathol. 2025 Jan;20(1):459-482. IF: 28.4Role of Fungi in Tumorigenesis: Promises and Challenges.www.annualreviews.org/doi/10.1146/annurev-pathmechdis-111523-023524 Mol Cancer. 2025 Jan 24;24(1):30. IF: 27.7The micro(nano)plastics perspective: exploring cancer development and therapy.www.biomedcentral.com/articles/10.1186/s12943-025-02230-z Nat Cancer. 2025 Jan 24. IF: 23.5Inhibition of ERα signaling induces lineage plasticity in vivo.www.nature.com/articles/s43018-024-00897-9 Nat Cancer. 2025 Jan 24. IF: 23.5TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states.www.nature.com/articles/s43018-024-00900-3 Neuro Oncol. 2025 Jan 24. IF: 16.4Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.www.academic.oup.com/neuro-oncology/article/7978292 Nat Commun. 2025 Jan 25;16:1025. IF: 14.7Diversity-oriented synthesis of stereodefined tetrasubstituted alkenes via a modular alkyne gem-addition strategy.www.nature.com/articles/s41467-025-56184-3 Nat Commun. 2025 Jan 25;16:1027. IF: 14.7Towards device technologies non-invasive to our daily lives.www.nature.com/articles/s41467-025-56423-7 Lancet Reg Health Eur. 2025 Jan 23;49:101212. IF: 13.6Dose-dense anthracycline- and taxane-based chemotherapy remains the preferred treatment for selected patients with high-risk early breast cancer.www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00004-3 Biomaterials. 2025 Jan 23;317:123116. IF: 12.8Inhibition of PDT-induced PGE2 surge for enhanced photo-immunotherapy.www.sciencedirect.com/science/article/pii/S0142961225000353 Cancer Res. 2025 Jan 24. IF: 12.5Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.www.aacrjournals.org/cancerres/article/751230 Med Image Anal. 2025 Jan 23;101:103466. IF: 10.7Enhancing lesion detection in automated breast ultrasound using unsupervised multi-view contrastive learning with 3D DETR.www.sciencedirect.com/science/article/pii/S1361841525000143 JAMA Netw Open. 2025 Jan 24;8(1):e2456142. IF: 10.5Incidence Rate Trends of Breast Cancer Overall and by Molecular Subtype by Race and Ethnicity and Age.www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829508 J Control Release. 2025 Jan 24;379:678-695. IF: 10.5Microneedle patch-involved local therapy synergized with immune checkpoint inhibitor for pre- and post-operative cancer treatment.www.sciencedirect.com/science/article/pii/S0168365925000628 J Immunother Cancer. 2025 Jan 23;13(1):e010833. IF: 10.3Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care.jitc.bmj.com/content/13/1/e010833 Cancer Treat Rev. 2025 Jan 23;133:102880. IF: 9.6Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion.www.cancertreatmentreviews.com/article/S0305-7372(25)00002-7/fulltext Biomark Res. 2025 Jan 23;13(1):14. IF: 9.5Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes.www.biomedcentral.com/articles/10.1186/s40364-025-00724-y
